National Academies Press: OpenBook
« Previous: Glossary
Suggested Citation:"A Agenda." Institute of Medicine. 2011. Nanotechnology and Oncology: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13037.
×

A

Agenda

National Cancer Policy Forum Workshop
Institute of Medicine
July 12–13, 2010

The Liaison Capitol Hill Hotel
“The Hill” Conference Room
415 New Jersey Avenue NW
Washington, DC 20001

DAY 1, July 12

 

8:30 am Breakfast Available

9:00 am

Welcome

Edward Benz, planning committee chair, Dana Farber Cancer Institute



Session 1

Introduction to Nanotechnology and Nanomedicine
Moderator: Edward Benz, Dana Farber Cancer Institute



9:15 am

Historical View of Nanotechnology and Nanomedicine
Mauro Ferrari, University of Texas Health Science Center–Houston



9:45 am

The NCI Nanotechnology Alliance for Cancer:
Making Personalized Cancer Medicine a Reality
Anna Barker, National Cancer Institute



10:15 am BREAK

10:30 am Cancer Nanotechnology Beyond the NCI
Steven Curley, MD Anderson Cancer Center

Suggested Citation:"A Agenda." Institute of Medicine. 2011. Nanotechnology and Oncology: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13037.
×
Session 2 Clinical Research and Translational Science—
Accommodating and Enabling Nanotechnology
Moderator: Steven Curley,MD Anderson Cancer Center

Each speaker is asked to comment on the flow of translational research:

– What does a clinical investigator planning trials incorporating nanotechnology need to know?

– What will it take to get there?

Clinical Research Perspective
Speakers are asked to address the following questions:

– What do clinical researchers need to know about nanotechnology?

– What tests must nano-materials themselves undergo?

– What tests must nano-materials themselves undergo?

– What are potential and known risks with use of nanotechnology and how are unknowns being addressed?

– Are there real advantages to nanotechnology (as diagnostics, screening tools, therapeutics, etc.)?

 

11:00 am Nanoparticles as Therapeutic Platforms Steve Libutti, Albert Einstein School of Medicine

11:30 am Biologic Barriers to In Vivo Nanomedicine Delivery: Major Hurdles for Clinical Translation King Li, The Methodist Hospital Research Institute

12:00 pm LUNCH

Industry Perspective
Speakers are asked to address the following questions:

– How are companies thinking about moving nanotechnology

– How are companies thinking about moving nanotechnology products through the pipeline from proof of concept to development for clinical trials?

– What is the current state of preclinical studies in testing efficacy and toxicity?

– What are the long-term effects of these incredibly stable products?

– What are the long-term effects of these incredibly stable products?

– Is it known what happens in degradation processes?

– Is it known what happens in degradation processes?

 

1:00 pm The nab-Platform: From Bench to the Clinic and Beyond
Neil Desai,
Abraxis Biosciences

Preventive Medicine Perspective
Speakers are asked to address the following questions:

– What issues, opportunities, and known efforts exist

– What issues, opportunities, and known efforts exist within this domain?

Suggested Citation:"A Agenda." Institute of Medicine. 2011. Nanotechnology and Oncology: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13037.
×

– What challenges and unique enhancements does nanotechnology provide in this area?

– How can nanotechnology be used to improve health (i.e., through environmental remediation or to make safer foods, etc.)?

 

1:30 pm Nanotechnology and Cancer Prevention Ernie Hawk,MD Anderson Cancer Institute

Diagnostics and Therapeutics Discovery and Development Perspective
Speakers are asked to address the following questions:

– What issues, opportunities, and known efforts exist within this domain?

– What challenges and unique enhancements does nanotechnology provide in this area?

 

2:00 pm Opportunities for Reproducibility and Uniformity of Therapeutics and Vaccines Using Templated Nanomanufacturing Methods Joseph DeSimone, University of North Carolina
2:30 pm James Heath, California Institute of Technology

3:00 pm BREAK

Radiology and Laboratory Medicine Perspective
Speakers are asked to address the following questions:

– What issues, opportunities, and known efforts exist within this domain?

– What challenges and unique enhancements does nanotechnology provide in this area?

 

3:15 pm Microfluidic Approaches for Single Cell Analysis Scott Manalis,Massachusetts Institute of Technology

3:45 pm Magnetic Nanoparticles and Magnetic Resonance: From Contrast Agents to Assays to Sensors Lee Josephson, Harvard University

4:15 pm Panel Discussion—Ideas for making progress in the next 2, 10, and 20 years
All session speakers

4:45 pm Adjourn until Tuesday

Suggested Citation:"A Agenda." Institute of Medicine. 2011. Nanotechnology and Oncology: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13037.
×

DAY 2, July 13

 

8:00 am Breakfast Available

8:20 am Welcome Back

Session 3 Government Research Initiatives, Regulation, and International Standards
Moderator: Mauro Ferrari,University of Texas Health Science Center–Houston

Government Research Initiatives Speaker is asked to address the following questions:

– Describe the role of the Nanotechnology Characterization Laboratory and how it may evolve over the next 10 years.

– Describe some challenges overcome and current challenges facing the laboratory.

– How do these lessons extend to other government research initiatives?

 

8:30 am NCI’s Nanotechnology Characterization Lab: Lessons Learned and Future Directions
Scott McNeil,
Nanotechnology Characterization Laboratory

9:00 am Discussion with Scott McNeil, Piotr Grodzinski, Mauro Ferrari, and Anna Barker

9:30 am BREAK

International Standards: Cooperative Research and Regulation: Lessons and Challenges
Speakers are asked to address the following questions:

– What lessons can US regulators learn from regulation of nanotechnology in other countries?

– What policies support cooperative research internationally?

– What policies support product development and regulation

– What policies support product development and regulation internationally?

 

9:45 am Crossroad of Nanomedicine: Nanosafety and Policy Yuliang Zhao, Chinese Academy of Sciences, and Research Center for Cancer Nanotechnology

Suggested Citation:"A Agenda." Institute of Medicine. 2011. Nanotechnology and Oncology: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13037.
×
10:15 am Successful Transfer of Innovative Technologies from Lab-Patient-Routine Use: Lessons Learnt and Global Opportunities
Ruth Duncan,
Cardiff, UK

10:45 am Nanomedicines Challenges and Opportunities in a Global Development Environment
Rogério Gaspar,
Research Institute for Medicines and Pharmaceutical Sciences

11:15 am Discussion

11:30 am WORKING LUNCH (boxed lunches available)

Regulatory Challenges and Safety
Speakers are asked to address the following questions:

– What are regulators looking for?

– How is nanotechnology being handled?

– What concerns do the public have and how are they best addressed?

 

11:45 am Kristen Kulinowski,Rice University

12:15 pm Jonathan Sackner-Bernstein,Food and Drug Administration

12:45 pm Discussion

1:00 pm Workshop Wrap-up Moderator: Mauro Ferrari,University of Texas Health Science Center–Houston

1:15 pm Adjourn
Suggested Citation:"A Agenda." Institute of Medicine. 2011. Nanotechnology and Oncology: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13037.
×

This page intentionally left blank.

Suggested Citation:"A Agenda." Institute of Medicine. 2011. Nanotechnology and Oncology: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13037.
×
Page 83
Suggested Citation:"A Agenda." Institute of Medicine. 2011. Nanotechnology and Oncology: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13037.
×
Page 84
Suggested Citation:"A Agenda." Institute of Medicine. 2011. Nanotechnology and Oncology: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13037.
×
Page 85
Suggested Citation:"A Agenda." Institute of Medicine. 2011. Nanotechnology and Oncology: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13037.
×
Page 86
Suggested Citation:"A Agenda." Institute of Medicine. 2011. Nanotechnology and Oncology: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13037.
×
Page 87
Suggested Citation:"A Agenda." Institute of Medicine. 2011. Nanotechnology and Oncology: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13037.
×
Page 88
Next: B Speaker and Planning Committee Biographies »
Nanotechnology and Oncology: Workshop Summary Get This Book
×
Buy Paperback | $31.00 Buy Ebook | $24.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

One way scientists are working to overcome challenges in cancer treatment and improve cancer care is through nanotechnology. Nanotechnology, engineered materials that make use of the unique physical properties, presents a new array of medical prospects that will revolutionize cancer prevention, diagnosis, and treatment practices. Giving new hope to patients, practitioners, and researchers alike, nanotechnology has the potential to translate recent discoveries in cancer biology into clinical advances in oncology. While public investments in nanotechnology for cancer continue to increase, medical products based on nanotechnology are already on the market.

The National Cancer Policy forum held a workshop July 12-13, 2010, to explore challenges in the use of nanotechnology in oncology. Nanotechnology and Oncology evaluates the ongoing discussion on the role of nanotechnology in cancer as it relates to risk management, treatment, and regulatory policy. Assessments on nanomedicine and the physical properties of nanomaterials were presented during the workshop, along with an appraisal of the current status of research and development efforts.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!